When was Vyome Therapeutics founded?

Vyome Therapeutics was founded in 2010 and raised its 1st funding round within a year of its incorporation.

Where is Vyome Therapeutics located?

Vyome Therapeutics is headquartered in Princeton, United States. It is registered at C4-201,Akshar Pavilion Priya Cinema Road, Vadodara, Vadodara, Gujarat, India, 390021.

Who is the current CEO of Vyome Therapeutics?

Venkateswarlu Nelabhotla of Vyome Therapeutics. They have also founded 1 company.

Which legal entities is Vyome Therapeutics associated with?

Vyome Therapeutics is associated with VYOME BIOSCIENCES PRIVATE LIMITED and 2 others.

How many employees does Vyome Therapeutics have?

As of May 31, 2026, the latest employee count at Vyome Therapeutics is 20.

Is Vyome Therapeutics a funded company?

Vyome Therapeutics is a funded company, having raised a total of $62.9M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 02, 2010.

When was the latest funding round of Vyome Therapeutics?

Vyome Therapeutics' latest funding was a $***** Series D round on Dec 31, 2018, with participation from 5 investors. Its primary sector is Dermatology. In United States, the Dermatology sector has seen $197M in funding in 2026 to date.

What is the annual revenue of Vyome Therapeutics?

Annual revenue of Vyome Therapeutics is less than ₹10 Cr as on Mar 31, 2025

Where does Vyome Therapeutics rank among its competitors?

Vyome Therapeutics ranks 254th amongst 3077 active competitors, of which 1040 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Vyome Therapeutics?

Vyome Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Vyome Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for the treatment of the immuno-inflammatory conditions. It offers locally-acting drug product which include VB-1953 gel for malignant fungating wound and inflammatory acne, VT1908 for steroid-refractory incompatibe uveitis, and for other rare immunological conditions including arthritis, diabetes, psoriasis, Crohn's disease, blindness, lupus, and others.

Website: vyometx.com
Social
Email ID: *****@vyometx.com
Phone Number: +1 **********
Registered Address: C4-201,Akshar Pavilion Priya Cinema Road, Vadodara, Vadodara, Gujarat, India, 390021

Key Metrics

Founded Year

2010

Location

Princeton, United States

Stage

Public

Total Funding

$62.9M in 7 rounds

Latest Funding Round

Series D, Dec 31, 2018, $*****

Investors

IndoUS Venture Partners & 12 more

Ranked

254^th among 3077 active competitors

Annual Revenue

0 - ₹10 Cr as on Mar 31, 2025

Employee Count

20 as on May 31, 2026

Investment & Acquisitions

Oculo Health

Similar Companies

LEO Pharma & 834 more

Exit Details

Public

View Vyome Therapeutics' full profile

Vyome Therapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
VYOME THERAPEUTICS LIMITED CIN: U73100GJ2017PLC098900 , India, Active	Aug 30, 2017	0 - ₹10 Cr (As on Mar 31, 2025)	6 (As on Jul 31, 2025)
VYOME BIOSCIENCES PRIVATE LIMITED CIN: U33110GJ2010PTC099141 , India, Active	Aug 19, 2010	0 - ₹10 Cr (As on Mar 31, 2025)	1 (As on Dec 31, 2022)
VYOME THERAPEUTICS INC. CIN: 6519686 , United States, Active		-	-	-

Vyome Therapeutics got listed on Aug 15, 2025.

Click here to take a look at Vyome Therapeutics's IPO in detail

Vyome Therapeutics has raised a total funding of $62.9M over 7 rounds. Its first funding round was on Nov 02, 2010. Its latest funding round was a Series D round on Dec 31, 2018 for $*****. 5 investors participated in its latest round. Vyome Therapeutics has 13 institutional investors.

Here is the list of recent funding rounds of Vyome Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 31, 2018	2052585	Series D	9496590	1864356	1924086	2527199
Dec 21, 2018	8913282	Series C	3179711	6772025	3575613	5021245
Dec 14, 2018	6741694	Series C	8311412	6679475	3643768	5452746

Access funding benchmarks and valuations. Sign up today!

View details of Vyome Therapeutics's funding rounds and investors

The founders of Vyome Therapeutics are Shiladitya Sengupta and Venkateswarlu Nelabhotla. Venkateswarlu Nelabhotla is the CEO of Vyome Therapeutics.

Here are the details of Vyome Therapeutics' key team members:

Shiladitya Sengupta: Co-Founder of Vyome Therapeutics. They serve on the board of 1 company.
Contact Info: 1 phone number
Venkateswarlu Nelabhotla: Co-Founder & CEO of Vyome Therapeutics.
Contact Info: 1 email address

Vyome Therapeutics' Board of Directors

Vyome Therapeutics's board has 4 active members. Shiladitya Sengupta and Venkateswarlu Nelabhotla are part of team and Ranjana Kumar and Krishna Kumar Gupta are independent board members.

Here is the list of Vyome Therapeutics' board of directors:

Name	Type	Representing	Status	Duration
Shiladitya Sengupta	Team	-	Current	15y 11m
Venkateswarlu Nelabhotla	Team	-	Current	7y 4m
Ranjana Kumar	Independent board member	-	Current	15y 8m
f{lhqtw	Independent board member	-	Current	3y 3m

View details of Vyome Therapeutics's Founder profiles and Board Members

Vyome Therapeutics' employee count trend

Vyome Therapeutics has 20 employees as of May 26. Here is Vyome Therapeutics's employee count trend over the years:

Employee count trend for Vyome Therapeutics

Uncover Vyome Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vyome Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Vyome Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
6th	LEO Pharma 1908, Copenhagen (Denmark), Late Stage	Developer of drugs for treating dermatology diseases	$560M	Nordic Capital	71/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Livzon Pharmaceutical & 5 others	71/100
254th	Vyome Therapeutics 2010, Princeton (United States), Public	Developer of therapeutics for the immuno-inflammatory conditions	$62.9M	Perceptive Advisors, Sabre Partners & 11 others	57/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Vyome Therapeutics's competitors? Click here to see the top ones

Founders own 5.22%, Funds (largest shareholder) own 80.66%, ESOP Pool own 6.02% and Other Investors own 8.11%. The net worth of Vyome Therapeutics's founders is INR 13.4Cr as of Sep 28, 2016.

Shareholders Name	Post Round Holding %	Net worth	Cumulative Investment	Realised Returns	Unrealised Returns	Return Multiple
Founder	5.22%	13.4Cr	47842	47526	42577	63261
Shiladitya Sengupta	88353	24479	61862	14050	65200	28960
Fund	80.66%	208Cr	2213554	1300635	6292354	6908632
Kalaari Capital	5489892	3024959	3523426	9997283	2732802	3836102
Perceptive Advisors	7080782	8339378	3550985	8126022	1581910	7272064
Sabre Partners	7578654	5034829	4296029	8566463	7792434	4106606
Romulus Capital	9202	2242	4738	1716	5093	2973
ESOP Pool	6.02%	15.5Cr	319238	789316	698153	258702
Other Investors	8.11%	20.9Cr	9355157	4728621	4384850	8523422
Total	100.00%	257Cr	4069728	9088396	1510995	9484397

To unlock detailed Cap Table of Vyome Therapeutics Sign up today!

Notes: The column Net Worth represents the net worth of investments made by that entity, as per the latest cap table.

Disclaimer

View more details of Vyome Therapeutics's Shareholding

Vyome Therapeutics has acquired Oculo Health. Vyome Therapeutics has not made any investments as of now.

Here is the latest report on Vyome Therapeutics's geography:

Free

US FinTech Semi Annual Funding Report

Edition: H1, 2026 (42 Pages)

View all reports related to Vyome Therapeutics

Media has covered Vyome Therapeutics for a total of 21 events in the last 1 year, 9 of them have been about company updates and 3 about people movement.